Clinical Trials
5 trialsNCT06966700 2026-05-22
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT07441460 2026-04-08
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
Shanghai JMT-Bio Inc.
Phase 3 Recruiting
NCT05862064 2025-07-16
A Multi-center, Randomized, Open-label, Phase III Study Comparing PD-1 Inhibitor Combined With Antivascular Therapy and Anthracycline/Taxane-based Adjuvant Chemotherapy Versus Anthracycline/Taxane-based Adjuvant Chemotherapy Alone in Patients With Operable Triple-negative Breast Cancer
Fudan University
Phase 3 Recruiting
NCT05883852 2023-06-27
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
Fudan University
Phase 3 Recruiting
NCT05901428 2023-06-15
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
Fudan University
Phase 3 Recruiting